In conclusion, given the importance of inhibiting ER activity and signaling in the treatments of breast cancer and other ER-related diseases, developing more potent and selective inhibitors of ER to overcome resistance and improve treatment outcomes is still of great importance. This evidence concerns the gene ESR1 and breast carcinoma.